At the Hebrew University of Jerusalem, a $2.3 million investment has allowed Lumir Lab, a cannabinoid research lab, to set up on campus to study cannabinoid-based treatments. The investment came from Asana Bio Group Ltd., an Israeli company with a specialty in medical cannabis ventures.

The lab will provide analyses, solutions, and clinical validation to companies operating in the medical cannabis industry. Lumir Lab will also create cannabinoid and terpene profiling as well as product formulations.

The lab is headed by Lumír Ondřej Hanuš, a world-leading chemist and leading authority in the field of cannabis research. Lumír Hanuš along with William Anthony Devane became the first to identify and isolate Anandamide, the first endocannabinoid to be found in the human brain.

What type of Cannabinoid-based treatments will Lumir Labs conduct?

Lumir Lab collaborated with Gynica, a company that specializes in the research of cannabis and women’s health. Gynica and Lumir Lab will collaborate on research for treating endometriosis. Endometriosis is a condition where tissue that normally lines the inside of your uterus — the endometrium — grows outside your uterus resulting in severe pain and moderate to heavy blood loss.

The lab aims to set an international standard for clinically backed cannabis treatments according to a statement provided by Yotam Hod. Yotam Hod is the son of Moshe Hod, the head professor of OBGYN at Gynica.

Asana Bio Group Ltd. plans to use the intellectual property created in the lab to manufacture and market in Europe.

This is a huge step for the CBD community. Israel has been one of the leading countries to conduct research on Cannabis. At a time when the United States is falling behind other countries, it is great to see further research on CBD and other cannabinoids.